Connect your patients with these organizations that provide vital support to the metastatic breast cancer (mBC) community. Each site offers different types of helpful information.
Click or tap to learn more about each organization.
Tigerlily Foundation’s mission is to educate, advocate for, empower, and support young women–before, during, and after breast cancer; and our vision is to end disparities of age, stage, and color.
Unite For HER
Unite for HER’s mission is to enrich the health and well-being of those diagnosed with breast and ovarian cancer–for life, by funding and delivering integrative therapies.
The Metastatic Breast Cancer Alliance works to unify the efforts of our members to improve the lives of, and outcomes for, those living with metastatic breast cancer and their families through increasing awareness and education about the disease, and progressing research focused on extending life, enhancing quality of life and ultimately... to cure.
Living Beyond Breast Cancer
Living Beyond Breast Cancer is a national nonprofit organization that fulfills the mission of providing trusted information and a community of support through on-demand, emotional, practical, and evidence-based content that is meaningful to those newly diagnosed, in treatment, post-treatment, and living with metastatic disease.
Young Survival Coalition
YSC is an international organization dedicated to strengthening the community, addressing the unique needs, and improving the quality of life for young adults diagnosed with breast cancer age 40 and under.
Breast Cancer Trials
BreastCancerTrials.org is a nonprofit, easy-to-use clinical trial matching service that helps people with breast cancer learn about and find trials personalized to their situation. It is a program of Quantum Leap Healthcare Collaborative.
CancerCare is the leading national nonprofit organization offering free, professional support services to anyone affected by cancer—including case management, counseling, support groups, educational resources, financial assistance, and more.
These organizations are independent and not owned or controlled by MacroGenics, which makes no representations about the services and information they may offer. Their inclusion on this website is not intended as an endorsement of the organization or the services offered, nor is it an indication of the organization’s endorsement of MARGENZA.
MARGENZA Access Support is here to
help your patients with affordability issues
WARNING: LEFT VENTRICULAR DYSFUNCTION AND EMBRYO-FETAL TOXICITY
The most common adverse drug reactions (>10%) with MARGENZA in combination with chemotherapy are fatigue/asthenia (57%), nausea (33%), diarrhea (25%), vomiting (21%), constipation (19%), headache (19%), pyrexia (19%), alopecia (18%), abdominal pain (17%), peripheral neuropathy (16%), arthralgia/myalgia (14%), cough (14%), decreased appetite (14%), dyspnea (13%), infusion-related reactions (13%), palmar-plantar erythrodysesthesia (13%), and extremity pain (11%).
MARGENZA is a HER2/neu receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.
Please see full Prescribing Information, including Boxed Warning.
You are about to go to a website that is operated by an independent third party. Your activities on the external website will be managed by its policies and practices. By clicking “Continue,” you will go to the external website.